Table 2.
Toxicity and treatment emerging adverse events [TEAE]
| RT | TMZ | |||||
|---|---|---|---|---|---|---|
| (N=228) | (N=235) | |||||
| Hematological toxicity, N(%) | Gr1–2 | Gr3 | Gr4 | Gr1–2 | Gr3 | Gr4 |
| Leukopenia | 12(5.3) | 120(51.1) | 8(3.4) | 1(0.4) | ||
| Neutropenia | 6(2.6) | 1(0.4) | 80(34) | 6(2.6) | 4(1.7) | |
| Thrombocytopenia | 8(3.4) | 4(1.7) | 7(3.0) | |||
| Anemia | 7(3.1) | 58(24.7) | 1(0.4) | 1(0.4) | ||
| Other TEAE, N(%) | ||||||
| Allergy/Immunology | 3(1.3) | 11(4.7) | 1(0.4) | |||
| Auditory/ear | 37(16.2) | 4(1.8) | 35(14.9) | 1(0.4) | ||
| Cardiac(general) | 10(4.4) | 11(4.7) | 2(0.9) | |||
| Constitutional symptoms | 141(61.8) | 8(3.5) | 159(67.7) | 15(6.4) | 1(0.4) | |
| Dermatology/skin | 112(49.1) | 73(31.1) | 4(1.7) | |||
| Endocrine | 9(3.9) | 12(5.1) | ||||
| Gastrointestinal | 66(28.9) | 4(1.8) | 158(67.2) | 10(4.3) | ||
| Hemorrhage/bleeding | 8(3.4) | |||||
| Hepatobiliar/pancreas | 2(0.9) | |||||
| Infection | 23(10.1) | 2(0.9) | 66(28.1) | 7(3.0) | 1(0.4) | |
| Lymphatics | 1(0.4) | 1(0.4) | 9(3.8) | |||
| Metabolic/laboratory | 1(0.4) | 2(0.9) | 4(1.7) | |||
| Musculoskeletal/soft tissue | 20(8.8) | 2(0.9) | 21(8.9) | 2(0.9) | ||
| Neurology | 134(58.8) | 25(11.0) | 3(1.3) | 125(53.2) | 36(15.3) | 5(2.1) |
| Ocular/visual | 36(15.8) | 46(19.6) | ||||
| Pain | 107(46.9) | 6(2.6) | 121(51.5) | 7(3.0) | ||
| Pulmonary/upper respiratory | 13(5.7) | 1(0.4) | 42(17.9) | 1(0.4) | ||
| Renal/genitourinary | 4(1.8) | 2(0.9) | 16(6.8) | |||
| Secondary malignancy | 1(0.4) | 1(0.4) | 4(1.7) | |||
| Sexual/reproductive function | 7(3.1) | 11(4.7) | 4(1.7) | |||
| Surgery/intra-operative injury | 2(0.9) | |||||
| Syndromes (flu-like, somnolence) | 3(1.3) | 12(5.1) | ||||
| Vascular | 2(0.9) | 1(0.4) | 1(0.4) | 1(0.4) | ||
An individual patient may have experienced diverse and multiple toxicities, thus the number of patients affected by toxicity is lower.